Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.
Research output: Contribution to journal › Article
Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it with treatment responses.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Cancer Research and Clinical Oncology|
|Early online date||2016 Jan 8|
|Publication status||Published - 2016|